[go: up one dir, main page]

WO2008120264A1 - Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures - Google Patents

Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures Download PDF

Info

Publication number
WO2008120264A1
WO2008120264A1 PCT/IT2008/000217 IT2008000217W WO2008120264A1 WO 2008120264 A1 WO2008120264 A1 WO 2008120264A1 IT 2008000217 W IT2008000217 W IT 2008000217W WO 2008120264 A1 WO2008120264 A1 WO 2008120264A1
Authority
WO
WIPO (PCT)
Prior art keywords
misoprostol
burns
stings
skin lesions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2008/000217
Other languages
English (en)
Inventor
Mario Immacolato Paternuosto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008120264A1 publication Critical patent/WO2008120264A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Definitions

  • the present invention relates to misoprostol-based pharmaceutical preparations for the topical treatment of skin lesions from stings and superficial burns.
  • Misoprostol i.e., methyl 7- [3-hydroxy-2 (4- hydroxy-4-methyloct-l-enyl) -5-oxocyclopentyl] heptanoate, is a synthetic prostaglandin of formula C22H38O5 and with a molecular weight of 382.5 g/mol. Its metabolism and bioavailability are at the moment unknown. When it is assumed by traditional routes, i.e., oral, sublingual or vaginal, its half-life in the organism is 20-40 minutes and 80% thereof is eliminated through the kidneys .
  • Prostaglandins are fatty acids that act where they are produced and at extremely low concentrations. Arachidonic acid from which they originate is present in the phospholipids of the cell membranes, from which it is released by the action of hydrolases and phospholipases .
  • Prostaglandins form part of a class of biochemical mediators, the intimate mechanisms and interactions of which have for some time been the subject of study.
  • prostaglandins can express in the biological field different effects not only in a guantitative sense but also in a qualitative sense, frequently acting in opposite ways with respect to one another on one and the same organ.
  • the effect of one and the same prostaglandin can vary according to the dose, the organ to which the reactive tissue belongs, and the physiological or pathological state of said organ.
  • prostaglandins amongst which misoprostol, or of pharmaceutically acceptable salts of prostaglandins themselves, as active principles in pharmaceutical preparations that can be administered by oral, rectal, and topical route, and that are effective in combating pruritis as symptom of inflammations of the skin, such as knettle rash, eczema, psoriasis, dermatosis, as likewise atopical symptoms, such as atopical dermatites and atopical conjunctivites .
  • the dosages indicated are comprised between 0.1 ⁇ g and 100 ⁇ g per administration, which may even be repeated many a day.
  • prostaglandins have a very short life in the organism because they are metabolized. If, however, they are used in the form of ointments, they enable a continuous and gradual release of the substance.
  • prostaglandins can be very conditioned by the dosage and by the habitat where they act, and by the interaction with other prostaglandins.
  • the inventor has assessed the possibility of applying high concentrations of a synthetic analogue of prostaglandins, such as misoprostol, over a prolonged time, into the area of the skin involved by superficial burns and lesions deriving from insect bytes and stings, verifying the effects and tolerability thereof.
  • a synthetic analogue of prostaglandins such as misoprostol
  • misoprostol used by topical route in the form of ointment has proven capable of controlling rapidly the typical burning pain and of speeding up healing of skin lesions from burns, guaranteeing in a high percentage of patients with second- degree burns a complete healing without leaving any signs.
  • Misoprostol once again at a high dose, has also proven able to reduce the times of healing of skin lesions from insect bytes and stings, guaranteeing in a high percentage of patients the immediate disappearance of the symptoms.
  • an object of the present invention is a pharmacological preparation of misoprostol for the treatment of skin lesions from stings and burns in the form of ointment, cream, gel, and paste, wherein misoprostol is present in an amount comprised between 10 and 25 mg per gram of preparation.
  • Topical treatment envisages the application on the surface of the skin involved by the lesion of an amount of ointment, cream, gel or paste, according to the cases, comprising an effective amount of misoprostol for the use according to the present invention comprised between 300 and 750 mg, to be repeated three times a day.
  • the purpose of the research was to assess the effectiveness in terms of time and after effects of healing (including the disappearance of the symptoms) of misoprostol for topical use in the treatment of first-degree and second- degree superficial burns.
  • PATIENTS AND METHODS thirty patients were enrolled who presented consecutively at a first- aid unit with superficial burns. All the patients recruited granted their written informed consent to participate in the study. Ten patients were male and twenty female. The age range was from 20 to 67 years old. Working activities: 7 cooks, 20 ironers, 3 mechanics. Of the patients 40% presented first-degree superficial burns, the remainder second-degree burns (the lesions were substancially located on the hands: only 30% on the back) .
  • the wounds were cleaned and medicated.
  • the patients received a misoprostol-based preparation (600 mg of misoprostol dissolved in 30 g of base cream) to be applied three times a day for ten days .
  • Disappearance of the symptoms was assessed at two hours, at three days, and at ten days, and healing of the lesions, understood as disappearance of the erythema in the first-degree burns and of the blisters in the second-degree burns, at three and ten days.
  • the evaluation of the lesions was always made by the same physician both at the first examination and at the subsequent ones.
  • misoprostol for topical use has proven able to reduce the times of healing of superficial burns, also guaranteeing a complete healing without leaving any sign in a high percentage of patients with second-degree burns.
  • the purpose of the research was to assess the effectiveness in terms of time and after effects of healing (including the disappearance of the symptoms) of misoprostol for topical use in the treatment of skin lesions from insect bytes and stings.
  • PATIENTS AND METHODS thirty patients were enrolled who presented for observation at a first-aid unit consecutively with skin lesions from insect bytes and stings.
  • the patients received a misoprostol-based preparation for topical use (600 mg of misoprostol dissolved in 30 g of base cream) to be applied three times a day for two days.
  • Misoprostol for topical use has proven able to reduce the times of healing of skin lesions from insect bytes and stings, guaranteeing in a high percentage of patients immediate disappearance of the symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation pharmacologique de misoprostol pour le traitement de lésions de la peau provenant de morsures et de dards d'insectes et de brûlures superficielles sous la forme d'une pommade, d'une crème, d'un gel et d'une pâte, le misoprostol étant présent dans une quantité comprise entre 10 et 25 mg par gramme de préparation.
PCT/IT2008/000217 2007-04-02 2008-04-01 Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures Ceased WO2008120264A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000007A ITCE20070007A1 (it) 2007-04-02 2007-04-02 Nuova indicazione per l'uso orale del misoprostolo nel trattamento del prurito quale sintomo di patologie non dermatologiche primitive e per l'uso topico delle ustioni
ITCE2007A000007 2007-04-02

Publications (1)

Publication Number Publication Date
WO2008120264A1 true WO2008120264A1 (fr) 2008-10-09

Family

ID=39644010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000217 Ceased WO2008120264A1 (fr) 2007-04-02 2008-04-01 Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures

Country Status (2)

Country Link
IT (1) ITCE20070007A1 (fr)
WO (1) WO2008120264A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
EP1477170A1 (fr) * 2002-02-22 2004-11-17 Taisho Pharmaceutical Co., Ltd Agents antiprurigineux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
EP1477170A1 (fr) * 2002-02-22 2004-11-17 Taisho Pharmaceutical Co., Ltd Agents antiprurigineux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIES, N.M. ET AL.: "Misoprostol therapeutics revisited", PHARMACOTHERAPY, vol. 21, no. 1, 2001, pages 60 - 73, XP009104186 *
FUKUSHIMA, R. ET AL.: "The degree of bacterial translocation is a determinant factor for mortality after burn injury and is improved by prostaglandin analogs", ANN SURG, vol. 216, 1992, pages 438 - 444, XP002491046 *

Also Published As

Publication number Publication date
ITCE20070007A1 (it) 2008-10-03

Similar Documents

Publication Publication Date Title
CA2604768C (fr) Formulations mucoadhesives contenant du xyloglucane utiles dans des dispositifs medicaux et dans des formulations pharmaceutiques
DE69529158T2 (de) Antivirale wundheilende zusammensetzungen die ein pyruvat, ein antioxidans, eine fettsaueremischung und eine antivirale verbindung enthalten
JPH10505057A (ja) 生物接着性創傷治癒組成物
TW201919633A (zh) 包含孟魯司特的局部調配物及與貽貝黏著蛋白的組合
JPH10502344A (ja) 抗角質溶解性創傷治癒組成物およびその調製および使用のための方法
EP1758603A1 (fr) Traitement de l'asthme et de l'arthrite et d'autres maladies inflammatoires
WO2008037262A1 (fr) Composition pharmaceutique et SON utilisations
CH683965A5 (it) Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US4508728A (en) Method of treating inflammatory diseases
JP2010530869A (ja) 過剰増殖性皮膚疾患の局所治療におけるヒアルロン酸のコンジュゲートの使用
FR2718023A1 (fr) Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
NZ504458A (en) Use of a mixture of a diol and an alpha-hydroxy acid in a semi-occluding vehicle for the treatment of hyperkeratotic skin diseases
WO2013155584A1 (fr) Composition pharmaceutique topique, procédé de production de cette composition pharmaceutique topique, utilisation de cette composition pharmaceutique topique et méthode de traitement topique du psoriasis, de la dermatite atopique ou des eczémas chroniques
JPH11506781A (ja) 創傷治癒を促進するためのシュードプテロシン類（ｐｓｅｕｄｏｐｔｅｒｏｓｉｎｓ）の使用
WO2017089475A1 (fr) Composition pharmaceutique cicatrisante à usage topique
WO2004022034A1 (fr) Preparation dermatologique pour le traitement de lesions cutanees
ES2392436T3 (es) Composiciones farmacéuticas para el tratamiento de ulceraciones crónicas
WO2008120264A1 (fr) Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures
WO2001074753A1 (fr) Derives synthetiques d'acide lunularique, medicaments contenant ces composes, procede de production desdits derives d'acide lunularique et leur utilisation
RU2151592C1 (ru) Лекарственное средство для лечения проктологических заболеваний
CN115040501A (zh) 顺-13-十八碳烯酸或其盐化合物在制备治疗受损皮肤和/或黏膜愈合的药物中的应用
EP2714706A1 (fr) Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques
EA008173B1 (ru) Способ и соединения, стимулирующие процессы заживления и ослабления воспаления
JP5998211B2 (ja) マグネシウムのスクロースオクタ硫酸エステル、その製造方法およびその医薬的および美容的使用
GB2144039A (en) Homocarnosine for treatment of inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751535

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751535

Country of ref document: EP

Kind code of ref document: A1